The use of ibrutinib before and after allogeneic stem cell transplantation

References

• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013 Dec;34(12):592–601.
   PubMed Web of Science ®Google Scholar
• Fu L, Lin-Lee YC, Pham LV, et al. Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006 Jun 1;107(11):4540–4548.
   PubMed Web of Science ®Google Scholar
• Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017 Sep 26;1(21):1867–1875.
   PubMedGoogle Scholar
• Mohamed AJ, Yu L, Bäckesjö CM, et al. Bruton‘s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58–73.
   PubMed Web of Science ®Google Scholar
• Satterthwaite AB, Witte ON. The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175(1):120–127.
   PubMedGoogle Scholar
• Novero A, Ravella PM, Chen Y, et al. Ibrutinib for B cell malignancies. Exp Hematol Oncol. 2014;3:4.
   PubMedGoogle Scholar
• Kawakami Y, Kitaura J, Hata D, et al. Functions of Bruton’s tyrosine kinase in mast and B cells. J Leukoc Biol. 1999;65:286–290.
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. Chem Med Chem. 2007;2(1):58–61.
   Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–13080.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–234.
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host disease. J Clin Invest. 2017;127(7):2452–2463.
   PubMed Web of Science ®Google Scholar
• Rozmus J, Schultz KR, Wynne K, et al. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the children’s oncology group study ASCT0031. Biol Blood Marrow Transplant. 2011;17(12):1804–1813.
   PubMed Web of Science ®Google Scholar
• Forcade E, Paz K, Flynn R, et al. An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017;2(12):e92111.
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018 Aug 14;2(15):2012–2019. .
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Cinar M, Hamedani F, Mo Z, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37:1271–1277.
   PubMed Web of Science ®Google Scholar
• Product Information: Imbruvica (ibrutinib) oral capsules. Sunnyvale, CA: Pharmacyclics Inc; Feb 2014.
   Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Rule S. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016 Feb 20;387(10020):770–778.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström‘s macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• https://www.drugs.com/history/imbruvica.html
   Google Scholar
• Fact Sheet: Breathrough Therapies. US Food and Drug Administration, [cited 2014 Sept 11] Available from: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm329491.htm
   Google Scholar
• Natarajan G, Oghumu S, Terrazas C, et al. A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
   Google Scholar
• Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 1;127(8):3052–3064.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286–22294.
   PubMed Web of Science ®Google Scholar
• Kaur V, Swami A. brutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. Ann Hematol. 2017 Jul;96(7):1175–1184.
   PubMed Web of Science ®Google Scholar
• Brown JR. How I treat CLL patients with ibrutinib. Blood.. 2018 Jan 25;131(4):379–386.
   PubMed Web of Science ®Google Scholar
• Mistry H, Nduka C, Connock M, et al. Venetoclax for treating chronic lymphocytic leukaemia: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 Apr;36(4):399–406.
   PubMed Web of Science ®Google Scholar
• Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol. 2016 Mar;91(3):330–340.
   PubMed Web of Science ®Google Scholar
• Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019;109:2415–2426.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017 Mar;4(3):e114–e126.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017 Jun;52(6):811–817.
   PubMed Web of Science ®Google Scholar
• D’Souza A Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2017. http://www.cibmtr.org
   Google Scholar
• Davids MS. How should we sequence and combine novel therapies in CLL? Hematol Am Soc Hematol Educ Program. 2017;2017:346–353.
   PubMedGoogle Scholar
• Martin P. Optimizing therapy for mantle cell lymphoma. Hematol Am Soc Hematol Educ Program. 2017;2017:304–309.
   PubMedGoogle Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123:2268–2273.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559–1563.
   PubMed Web of Science ®Google Scholar
• Mato A, Porter DL. A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood. 2015;1(26):478–485.
   Google Scholar
• Gribben JG. How and when I do allogeneic transplant in CLL. Blood. 2018 Jul 5;132(1):31–39.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22(12):2117–2125. doi: 10.1016/j.bbmt.2016.09.013.
   PubMedGoogle Scholar
• McKay P, Leach M, Jackson B, et al. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182:46–62.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 Sep 28;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Robinson S, Dreger P, Caballero D, et al. The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia. 2015 Feb;29(2):464–473.
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Sorror ML, Storer BE, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015 Oct 15;121(20):3709–3716.
   PubMed Web of Science ®Google Scholar
• Kruger WH, Hirt C, Basara N, et al. Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014;93:1587–1597.
   PubMed Web of Science ®Google Scholar
• Rule S, Cook G, Russell NH, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2018 Dec 17. DOI:10.1111/bjh.15723.
   Google Scholar
• Dreger P, Michallet M, Bosman P, et al.Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties. Bone Marrow Transplant. 2018;May 4 doi: 10.1038/s41409-018-0207-4
   Google Scholar
• Annalisa A, Simona B, Lara P, et al. Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature. Leuk Res Rep. 2017 Nov 15;8:21–23.
   PubMedGoogle Scholar
• Coutre S, O‘Brien S, Byrd JC, et al. Safety and efficacy of ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood. 2014;124:4697.
   Google Scholar
• Michallet M, Dreger P, Sobh M, et al. Salvage use of ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B cell malignancies: a study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) chronic malignancy and lymphoma working parties. Blood. 2016;128:4659.
   Google Scholar
• Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Dec 22;128(25):2899–2908.
   PubMed Web of Science ®Google Scholar
• Link CS, Teipel R, Heidenreich F, et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 Jun;51(6):793–798.
   PubMed Web of Science ®Google Scholar
• Quinquenel A, Sicre de Fontbrune F, Durot E, et al. Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic stem cell transplantation. Br J Haematol. 2017 Mar;176(6):997–999. Epub 2016 Mar 15.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10;122(15):2539–2549.
   PubMed Web of Science ®Google Scholar
• Center for International Blood and Marrow Transplant Research. CIBMTR 2014. [cited 2014 Aug 5] Available from: http://www.cibmtr.org.
   Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–233.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood. 2002;100(2):415–419.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Logan BR, Lee SJ, et al. Peripheral blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–1496.
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–2101.
   PubMed Web of Science ®Google Scholar
• Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074–5087.
   PubMed Web of Science ®Google Scholar
• Rhoades R, Gaballa S. The role of B cell targeting in chronic graft-versus-host disease. Biomedicines. 2017 Oct 17;5(4):pii: E61. .
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Flynn R, Du J, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov;124(11):4867–4876. Epub 2014 Oct 1.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Greinix H, Rabin B, et al. Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD task force. Bone Marrow Transplant. 2014 Jan;49(1):49–54.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015 Jan 22;125(4):606–615. .
   PubMed Web of Science ®Google Scholar
• Martin PJ, Inamoto Y, Carpenter PA, et al. Treatment of chronic graft-versushost disease: past, present and future. Korean J Hematol. 2011;46(3):153–163.
   PubMedGoogle Scholar
• Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074–5082.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546–554.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. Evaluation of thalidomide for treatment or prevention of chronic graftversus-host disease. Leuk Lymphoma. 2003;44(7):1141–1146.
   PubMed Web of Science ®Google Scholar
• Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a children’s oncology group study. Biol Blood Marrow Transplant. 2012;18(1):84–91.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Storer B, Carpenter P, et al. Treatment change as a predictor of outcome among patients with classic chronic graft-versus host disease. Biol Blood Marrow Transplant. 2008;14(12):1380–1384.
   PubMed Web of Science ®Google Scholar
• Inamoto Y, Flowers ME, Sandmaier BM, et al. Failure-free survival after initial systemic treatment of chronic graft-versus host disease. Blood. 2014;124(8):1363–1371.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase II randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667–2674.
   PubMed Web of Science ®Google Scholar
• Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.
   PubMed Web of Science ®Google Scholar
• Flowers MED, Deeg HJ. Chronic graft-versushost disease. In: Treleaven J, Barrett AJ, editors. Hematopoietic stem cell transplantation in clinical practice. Edinburgh, UK: Elsevier Ltd; 2009. p. 401–407.
   Google Scholar
• U.S. Food and Drug Administration: FDA expands ibrutinib indications to chronic GVHD. [cited 2017 Nov 8] Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569711.htm
   Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–2250.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Jabbour E, Saliba RM, et al. Ibrutinib in patients with mantle cell lymphoma and chronic lymphocytic leukemia with relapsed disease post allogeneic stem cell transplantation. Blood. 2015;126:4345, [abstract]
   Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT02959944
   Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT02869633
   Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT03267186
   Google Scholar
• Du J, Flynn R, Paz K, et al. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood. 2018;131(15):1743–1754.
   PubMed Web of Science ®Google Scholar